NEWS ARCHIVE
| California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2) $8 million grant funds development of NXC-201 in relapsed/refractory AL AmyloidosisLOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amylo… |
| Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024No change in patient enrollment timing LOS ANGELES, April 18, 2024 (GLOBE NEWSWIRE) — Nexc… |
| Nexcella Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board Dr. Sanchorawala co-authored landmark study of daratumumab (DARZALEX®) in AL Amyloidosis published in The New England Journal of Medicine, 2021 that led to it becoming a first-line standard of careLOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexc… |
| Nexcella Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board Dr. Radic led and authored landmark study demonstrating applicability of CAR-Ts in autoimmune diseases published in Science Translational Medicine, 2019 Dr. Radic is a recognized thought leader in autoimmune CAR-T cell therapy, antibody-mediated disorders and designing CAR-T studies … |
| Nexcella Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023 100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy in updated Phase 1/2 data as of December 10, 2023Best responder duration of response was 23.… |
| Nexcella Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance72 patients previously dosed with NXC-201 ex-U.S.First CAR-T program for light-chain (AL) AmyloidosisFavorable tolerability enables expansion into autoimmune indications LOS AN… |
| Nexcella Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients 100% overall response rate observed in relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapyUpdated results will be communicated at the presentation time December 10, 2023 LOS ANGELES, Nov. 06, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc. (Nasdaq:IMMX) (“Nexcella”, “Com… |
| Nexcella Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients 95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy98% overall response rate observed in relapsed/refractory multiple myeloma patients without extra-medullary diseaseUpdated results will be communicated at the p… |
| Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board Dr. Liedtke joins Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Stanford University Medical CenterDr. Liedtke is a recognized thought leader in CAR-T cell therapy and designing clinical trials in AL Amyloidosis and Multiple Myeloma LOS ANGELES,… |
| Nexcella Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site Successful completion supports expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S.NXC-201 is manufactured at our state-of-the-art cellular immunotherapy manufacturing facility in California LOS ANGELES, Oct. 16, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc. (… |
